- CA$39.97m
- CA$38.84m
- CA$28.86m
Brief: Medicure Announces FDA Approval Of Sodium Nitroprusside Injection
Brief: Medicure Reports Qtrly Earnings Per Share C$0.08
Brief: Medicure Announces Normal Course Issuer Bid
Brief: Medicure Reports Quarterly Earnings Of C$3.27/Share
Brief: Medicure Announces Further Up-Date On Prexxartan
Brief: Medicure Places PREXXARTAN Oral Solution Project On Hold
Brief: Medicure Posts Update On PREXXARTAN Launch
Brief: Medicure Announces FDA Approval Received For Prexxartan
Brief: Medicure Acquires License To Sell Cardiovascular Drug In The U.S.
Brief: Medicure net loss for quarter ended Sept 30, 2017 was $4.3 mln
Brief: Medicure says has repaid in full its loans with Manitoba Development and Crown Capital Fund
Brief: Medicure qtrly shr $0.08
Brief: Medicure exercises option to acquire additional interests in Apicore
Brief: Medicure provides update on Apicore purchase option
Brief: Medicure reports qtrly earnings per share $1.57
Brief: Medicure announces FDA approval for Apicore's generic tetrabenazine
Brief: Medicure provides secured loan in amount of US$9.8 mln to Apicore
Brief: Medicure announces filing of ANDA in collaboration with Apicore
Brief: Medicure exercises option to acquire majority interest in Apicore